# OnCo record imcgp100-202 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/imcgp100-202/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "imcgp100-202", "NCT03070392" ;
  schema:name "IMCgp100-202"@en ;
  schema:description "The first drug ever to extend life in metastatic uveal melanoma, and the first T-cell receptor-based medicine to win a phase 3."@en ;
  schema:url <https://onco.cc/trials/imcgp100-202/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03070392>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2103485> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2017-10-16" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/gp100/>, <https://onco.cc/targets/cd3/> ;
  onco:drugs <https://onco.cc/drugs/tebentafusp/> ;
  onco:companies <https://onco.cc/companies/immunocore/> ;
  onco:people <https://onco.cc/people/paul-nathan/>, <https://onco.cc/people/richard-carvajal/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-imcgp100-202-n-engl-j-med-2021/>, <https://onco.cc/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/> .